We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Guideline Recommends Placebo Arms for Short-Term Trials of Schizophrenia Drugs
EMA Guideline Recommends Placebo Arms for Short-Term Trials of Schizophrenia Drugs
November 9, 2012
The European Medicines Agency (EMA) is advising sponsors to use placebo arms, rather than active comparators, in short-term trials of schizophrenia drugs, according to a final guidance.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor